A team of researchers in India has proposed a new molecular framework for how Lewy bodies, the protein clumps that mark Parkinson's disease and related brain conditions, actually assemble inside neurons. Writing in the journal Communications Biology on January 8, 2026, the group, led by Sneha Jos and Sivaraman Padavattan of the Institute for Stem Cell Science and Regenerative Medicine in Bengaluru, report laboratory experiments with purified alpha-synuclein protein showing that disease-linked chemical forms of the protein behave very differently from the normal version. Lewy bodies contain not just alpha-synuclein but dozens of other proteins, lipids, and damaged cell parts, a mix that existing models, which focus mainly on alpha-synuclein clumping together on its own or separating into liquid-like droplets, have struggled to explain. The new paper argues those models miss a key ingredient: the protein's own hidden sticky patch. In the study, normal alpha-synuclein carried a hydrophobic segment, called the NAC region, that stayed folded away and shielded, so the protein interacted with only a limited set of partners in ways the researchers describe as functional. Two Parkinson's-linked forms of the protein tested in the same experiments, one carrying a chemical tag called S129 phosphorylation and one missing part of its tail, aggregated and separated into droplets faster, and the researchers say this points to that hidden segment being exposed. Once exposed, the altered protein bound broadly and nonspecifically to other proteins in the test tube and interfered with the ability of molecular chaperones, the cell's protein-repair machinery, to refold proteins normally. Based on these observations the authors propose what they call the Multifactorial Random Disorder Model, in which chemically altered alpha-synuclein acts as an indiscriminate trap that snowballs into a Lewy body by capturing whatever nearby proteins happen to be exposed, rather than following one fixed chemical pathway.